A buzzy new drug to help treat people with a peanut allergy was recommended for approval by an FDA advisory board this week. It would be the first government-approved method intended to combat these kinds of allergic reactions. The story behind that drug helps explain how the cost of many prescription drugs ends up being so high.
Guest: James Hamblin, staff writer at The Atlantic.
Slate Plus members get bonus segments and ad-free podcast feeds. Sign up now.
Hosted on Acast. See acast.com/privacy for more information.
